Tuomilehto J, Salonen J, Kuuisto P, Virtamo J, Manninen V, Mälkönen M
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):38-40. doi: 10.1177/00359157760690S209.
The efficacy of gemfibrozil as a hypolipidaemic agent was compared with that of clofibrate in a cohort of 80 subjects, half being treated with gemfibrozil and half with clofibrate. The majority of the subjects were either of the type IIa or IIb. Both drugs proved to be effective, though there were 13 non-responders in the clofibrate group, compared with 8 in the gemfibrozil group. The mean reduction in serum cholesterol induced by clofibrate was 23% and by gemfibrozil 19%. The corresponding falls in serum triglycerides were 36% and 43%. There were no serious side effects in either group. Analysed in this way, the relative efficiencies of gemfibrozil and clofibrate seem to be indistinguishable. Further studies are being directed towards evaluation of the individual responses to both treatments.
在一个由80名受试者组成的队列中，将吉非贝齐作为一种降血脂药物的疗效与氯贝丁酯进行了比较，其中一半受试者接受吉非贝齐治疗，另一半接受氯贝丁酯治疗。大多数受试者为IIa型或IIb型。两种药物均被证明有效，不过氯贝丁酯组有13名无反应者，而吉非贝齐组有8名。氯贝丁酯引起的血清胆固醇平均降低率为23%，吉非贝齐为19%。血清甘油三酯的相应下降率分别为36%和43%。两组均未出现严重副作用。以这种方式分析，吉非贝齐和氯贝丁酯的相对疗效似乎难以区分。进一步的研究旨在评估个体对两种治疗的反应。
